FDAFDA · Food and drugs·Recall number D-0855-2022
MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01
Published May 18, 2022 · Recall initiated: May 2, 2022
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Defective container: loose crimp defect, potential loss of container integrity.
What to do
Voluntary: Firm initiated · Letter
Recall details
- Manufacturer
- Amgen, Inc.
- Distributor
- Nationwide in the USA, Egypt and Lithuania.
- Lot
- Lots: 1142258, 1143196, Exp. 09/24
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Sell products like this?
Recalert watches your whole catalog for recalls like this one, automatically.